Form 4: MannKind CFO Christopher Prentiss Reports Acquisition of Common Stock and Performance-Based Restricted Stock Units

Christopher Prentiss, CFO of MannKind Corp, reports acquiring 119,000 shares of common stock and 145,000 performance-based restricted stock units.

Summary

• On May 13, 2025, Christopher Prentiss, the Chief Financial Officer of MannKind Corp, reported transactions involving the company's securities.
• Prentiss acquired 119,000 shares of common stock at $0.
• Following the transaction, Prentiss directly owns 353,193 shares of MannKind common stock, which includes 1,593 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2024.
• Prentiss also acquired 145,000 performance-based restricted stock units, which will vest on July 15, 2028, based on MannKind's total shareholder return (TSR) relative to the Russell 3000 Pharmaceutical & Biotechnology Index over a three-year period.
• The payout percentage of these units ranges from 0% to 300% of the target, depending on the percentile ranking of MannKind's TSR.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock transactions by an executive. The acquisition of shares could be seen as a positive signal, but it's not definitively bullish.

Positives

• The acquisition of shares by the CFO could be interpreted as a sign of confidence in the company's future prospects.

Future Outlook

The performance-based restricted stock units will vest on July 15, 2028, with the number of shares delivered depending on MannKind's TSR performance relative to the Russell 3000 Pharmaceutical & Biotechnology Index over the period from July 1, 2025, to June 30, 2028.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. The performance-based vesting of restricted stock units is a typical incentive mechanism used to align management's interests with those of shareholders.

Comparison to Industry Standards

• Performance-based equity compensation is a common practice among publicly traded companies, particularly in the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Biogen often use similar metrics, such as TSR relative to an industry index, to determine the vesting of performance-based equity awards.
• The vesting schedule and performance targets are generally aligned with long-term shareholder value creation.

Stakeholder Impact

• The acquisition of shares by the CFO could be viewed positively by shareholders as it aligns management's interests with theirs.
• The performance-based vesting of restricted stock units incentivizes management to improve the company's TSR, which benefits shareholders.

Key Dates

Keywords

MannKind, MNKD, Christopher Prentiss, CFO, Form 4, Stock, Restricted Stock Units, TSR, Russell 3000 Pharmaceutical & Biotechnology Index, Beneficial Ownership